<VariationArchive VariationID="1699258" VariationName="NM_000297.4(PKD2):c.1197del (p.Glu400fs)" VariationType="Deletion" Accession="VCV001699258" Version="3" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-07-23" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1691632" VariationID="1699258">
      <GeneList>
        <Gene Symbol="PKD2" FullName="polycystin 2, transient receptor potential cation channel" GeneID="5311" HGNC_ID="HGNC:9009" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>4q22.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88007635" stop="88077777" display_start="88007635" display_stop="88077777" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88928798" stop="88998930" display_start="88928798" display_stop="88998930" Strand="+" />
          </Location>
          <OMIM>173910</OMIM>
          <Haploinsufficiency last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-07-06" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=PKD2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000297.4(PKD2):c.1197del (p.Glu400fs)</Name>
      <CanonicalSPDI>NC_000004.12:88043334:A:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>4q22.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="4" Accession="NC_000004.12" start="88043335" stop="88043335" display_start="88043335" display_stop="88043335" variantLength="1" positionVCF="88043334" referenceAlleleVCF="GA" alternateAlleleVCF="G" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="4" Accession="NC_000004.11" start="88964487" stop="88964487" display_start="88964487" display_stop="88964487" variantLength="1" positionVCF="88964486" referenceAlleleVCF="GA" alternateAlleleVCF="G" />
      </Location>
      <ProteinChange>E400fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.11" sequenceAccession="NC_000004" sequenceVersion="11" change="g.88964487del" Assembly="GRCh37">
            <Expression>NC_000004.11:g.88964487del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000004.12" sequenceAccession="NC_000004" sequenceVersion="12" change="g.88043335del" Assembly="GRCh38">
            <Expression>NC_000004.12:g.88043335del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_008604.1" sequenceAccession="NG_008604" sequenceVersion="1" change="g.40668del">
            <Expression>NG_008604.1:g.40668del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000297.4" sequenceAccession="NM_000297" sequenceVersion="4" change="c.1197del" MANESelect="true">
            <Expression>NM_000297.4:c.1197del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000288.1" sequenceAccession="NP_000288" sequenceVersion="1" change="p.Glu400fs">
            <Expression>NP_000288.1:p.Glu400fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="non-coding">
          <NucleotideExpression sequenceAccessionVersion="NR_156488.2" sequenceAccession="NR_156488" sequenceVersion="2" change="n.1296del">
            <Expression>NR_156488.2:n.1296del</Expression>
          </NucleotideExpression>
          <MolecularConsequence ID="SO:0001619" Type="non-coding transcript variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2110112181" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000297.4(PKD2):c.1197del (p.Glu400fs) AND Polycystic kidney disease 2" Accession="RCV002273115" Version="3">
        <ClassifiedConditionList TraitSetID="3718">
          <ClassifiedCondition DB="MedGen" ID="C2751306">Polycystic kidney disease 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2022-02-02" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2022-02-02" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-08-08" MostRecentSubmission="2024-07-23">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="3718" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6943" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Polycystic kidney disease 2</ElementValue>
                <XRef ID="MONDO:0013131" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE, ADULT, TYPE II</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYSTIC KIDNEY DISEASE 2 WITH OR WITHOUT POLYCYSTIC LIVER DISEASE</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">APKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">PKD2</ElementValue>
                <XRef Type="MIM" ID="613095" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Autosomal dominant polycystic kidney disease (ADPKD) is generally a late-onset multisystem disorder characterized by bilateral kidney cysts, liver cysts, and an increased risk of intracranial aneurysms. Other manifestations include: cysts in the pancreas, seminal vesicles, and arachnoid membrane; dilatation of the aortic root and dissection of the thoracic aorta; mitral valve prolapse; and abdominal wall hernias. Kidney manifestations include early-onset hypertension, kidney pain, and kidney insufficiency. Approximately 50% of individuals with ADPKD have end-stage kidney disease (ESKD) by age 60 years. The prevalence of liver cysts increases with age and occasionally results in clinically significant severe polycystic liver disease (PLD), most often in females. Overall, the prevalence of intracranial aneurysms is fivefold higher than in the general population and further increased in those with a positive family history of aneurysms or subarachnoid hemorrhage. There is substantial variability in the severity of kidney disease and other extra-kidney manifestations.</Attribute>
                <XRef ID="NBK1246" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="18599" />
                <XRef ID="18599" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301424</ID>
                <ID Source="BookShelf">NBK1246</ID>
              </Citation>
              <XRef ID="C2751306" DB="MedGen" />
              <XRef ID="MONDO:0013131" DB="MONDO" />
              <XRef Type="MIM" ID="613095" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="5003548" SubmissionDate="2024-07-18" DateLastUpdated="2024-07-23" DateCreated="2022-08-08">
        <ClinVarSubmissionID localKey="vcgs/unit_1/hg38_NM_000297_3_PKD2_c_1197delA" localKeyIsSubmitted="1" />
        <ClinVarAccession Accession="SCV002557742" DateUpdated="2024-07-23" DateCreated="2022-08-08" Type="SCV" Version="2" SubmitterName="Victorian Clinical Genetics Services, Murdoch Childrens Research Institute" OrgID="500104" OrganizationCategory="laboratory" OrgAbbreviation="VCGS" />
        <AdditionalSubmitters>
          <SubmitterDescription OrgID="508197" SubmitterName="Shariant Australia, Australian Genomics" Type="behalf" OrganizationCategory="consortium" />
        </AdditionalSubmitters>
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-02-02">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with polycystic kidney disease 2 (MIIM#613095). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0201 - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). (SP) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0701 - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity. There are at least ten likely pathogenic and pathogenic NMD-predicted variants that have been reported (Decipher, ClinVar). (SP) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal dominant inheritance</Attribute>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="PKD2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="SubmitterVariantId">ALLELE_15023</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000297.3:c.1197delA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0013131" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>submission_32</SubmissionName>
          <SubmissionName>submission_45</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="5003548" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0013131" MappingRef="MONDO">
        <MedGen CUI="C2751306" Name="Polycystic kidney disease 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

